CIP
VRDN icon

Chartwell Investment Partners’s Viridian Therapeutics VRDN Stock Holding History

Chartwell Investment Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-39,600
Closed -$608K – 446
2023
Q3 		$608K Hold
39,600
– – 0.02% 384
2023
Q2 		$942K Buy
39,600
+6,001
+18% +$154K 0.03% 357
2023
Q1 		$855K Sell
33,599
-27,453
-45% -$880K 0.03% 356
2022
Q4 		$1.78M Buy
61,052
+3,488
+6% +$80.4K 0.07% 275
2022
Q3 		$1.18M Buy
+57,564
New +$1.03M 0.05% 329

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Chartwell Investment Partners's VRDN Position: Q4 2023 in Review

Chartwell Investment Partners sold out of Viridian Therapeutics (VRDN) in Q4 2023, closing a stake of 39,600 shares — an estimated $608K sold.

Chartwell Investment Partners first reported a position in VRDN in Q3 2022 and held it in 5 quarters. The position peaked at $1.78M in Q4 2022. 132 funds tracked by Wall St. Rank hold VRDN as of Q4 2023.

  • Chartwell Investment Partners reported no remaining Viridian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Chartwell Investment Partners sold 39,600 Viridian Therapeutics shares in Q4 2023, an estimated $608K.
  • Chartwell Investment Partners first reported a position in Viridian Therapeutics in Q3 2022 and held it in 5 quarters.
  • Chartwell Investment Partners's Viridian Therapeutics position peaked at $1.78M in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2023.

Based on Chartwell Investment Partners's 13F filing for Q4 2023, filed 15 Feb 2024.